Skip to main content
    M

    Marker Therapeutics Inc (MRKR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.84
    +0.01 (+0.97%)

    Market Cap: $13.82M

    Last updated: Nov 17, 2026 at 4:31 PM ET

    Marker Therapeutics Inc (MRKR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Marker Therapeutics (MRKR) has a market cap of $13.82M and an enterprise value of $4.78M. It kept -775.14% of revenue as net income over the last 12 months. Its share count is up 15.26% from a year earlier.

    Total Valuation

    Enterprise value is 65.43% below the market cap, as cash exceeds debt.

    Market Cap$13.82M
    Enterprise Value$4.78M
    Latest price (Nov 17, 2026)$0.84

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 47.12% a year over 2 years.

    Shares Outstanding19.31M
    Shares Change (YoY)+15.26%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+47.12%

    Valuation Ratios

    Sales and book value multiples are 14.6x and 1.5x. Its year-end P/S ranged from 2.2x to 617.8x from 2019 to 2025.

    P/S Ratio14.6x
    Forward P/S3.3x
    P/B Ratio1.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 9.36% over 52 weeks and trades 19.23% below its 50-day average.

    Beta (1Y)1.29
    52-Week Change-9.36%
    1-Month Change-30.28%
    3-Month Change-35.15%
    6-Month Change-39.81%
    5-Year Change-93.33%
    10-Year Change-98.04%
    Total Return (1Y)-9.36%
    Total Return (3Y CAGR)-33.53%
    Total Return (5Y CAGR)-41.89%
    Max Drawdown (1Y)-62.16%
    Max Drawdown (3Y)-86.10%
    Sharpe Ratio (1Y)-0.23
    Correlation with SPY (1Y)0.22
    50-Day Average$1.04
    200-Day Average$1.31
    52-Week Range$0.82 to $2.46
    RSI (14 Days)39.2
    Average Volume (20 Days)123.51K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.26x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.26x
    Quick Ratio6.26x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -81.44% over the last 12 months, against a 5-year average of -87.35%.

    Return on Equity (ROE)-81.44%
    Return on Assets (ROA)-68.43%
    Return on Capital Employed (ROCE)-86.45%
    ROE (5Y Average)-87.35%
    ROA (5Y Average)-61.80%
    ROIC (5Y Average)-75.95%
    Asset Turnover0.06x
    Receivables Turnover0.55x

    Scores

    MRKR has an Altman Z-Score of -48.64, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-48.64
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $1.10M over the last 12 months is down 51.00% from the 12 months before.

    Revenue$1.10M
    Revenue Growth (YoY)-51.00%
    Gross Profit$1.10M
    Operating Income-$11.81M
    Pretax Income-$12.91M
    Net Income-$8.55M
    EBITDA-$9.08M
    EBIT-$9.08M
    Reported EPS (TTM)-$0.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.00% of the $12.50M in total assets.

    Cash and Equivalents$9.04M
    Total Debt$0
    Net Cash$9.04M
    Net Cash Per Share$0.47
    Working Capital$10.50M
    Shareholder Equity$10.50M
    Book Value Per Share$0.54
    Total Assets$12.50M
    Total Liabilities$2.00M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$9.52M
    FCF Per Share-$0.57

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1069.94%.

    Gross Margin100.00%
    Operating Margin-1069.94%
    Pretax Margin-1169.59%
    Net Margin-775.14%
    EBITDA Margin-822.87%
    EBIT Margin-822.87%

    Growth

    Revenue grew 0.31% a year over 3 years.

    Revenue Growth (3Y CAGR)+0.31%
    Revenue Growth (5Y CAGR)+50.02%
    Book Value Per Share Growth (2Y CAGR)-16.64%
    Tangible Book Per Share Growth (2Y CAGR)-16.64%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-10 reverse split on Jan 27, 2023.

    Last Split DateJan 27, 2023
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 4 similar companies, MRKR has the 2nd highest P/S.

    P/S Ratio14.6x vs 5.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-51.00% vs -83.16% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 138.57% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+138.57%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRKR

    What is MRKR's market cap?

    Marker Therapeutics has a market cap of $13.82M. Its enterprise value, which adds debt and subtracts cash, is $4.78M.

    How many shares of MRKR are outstanding?

    Marker Therapeutics has 19.31M shares outstanding. The count is up 15.26% from a year earlier.

    Does MRKR pay a dividend?

    No. Marker Therapeutics does not pay a dividend.

    How much debt does MRKR have?

    Marker Therapeutics has $0 of total debt and $9.04M of cash and equivalents, a net cash position of $9.04M.